Effects of betamethasone on maternal plasma corticotropin releasing factor, ACTH and cortisol during pregnancy. 1987

P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York.

Corticotropin releasing factor immunoactivity (CRFi) has been identified in the plasma of women in the second half of gestation. There are several lines of evidence supporting a placental source for this hormone. Regulation of placental CRFi is poorly understood. In this study, the effect of a long-acting glucorticoid on the release of placental CRFi was investigated. Eleven women in the third trimester of pregnancy had plasma samples measured for CRFi, ACTH and cortisol before and after receiving 12 mg betamethasone. There was a significant decrease in ACTH (p less than 0.05) and cortisol levels (p less than 0.01) but no change in CRFi. It is concluded that the secretion of CRFi by the placenta is not inhibited by the administration of betamethasone while maternal levels of cortisol and ACTH are lowered. These results suggest that the acute regulation of placental CRFi is distinct from the regulation of hypothalamic CRF.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D001623 Betamethasone A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724) Betadexamethasone,Flubenisolone,Celeston,Celestona,Celestone,Cellestoderm

Related Publications

P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
October 1983, Endocrinologia japonica,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
January 2002, Journal of the Society for Gynecologic Investigation,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
September 1995, The Journal of clinical endocrinology and metabolism,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
January 1986, Peptides,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
April 1993, Acta endocrinologica,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
October 1992, Endocrinology,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
March 1985, Biological psychiatry,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
October 1984, The Journal of clinical endocrinology and metabolism,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
October 1984, The Journal of pediatrics,
P J Tropper, and R S Goland, and S L Wardlaw, and H E Fox, and A G Frantz
November 1986, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!